Company: IXHL
Filing Date: 2025-04-07
Form Type: 8-K
Source: 0001213900-25-029418
Chunk: 1

Company: Incannex Healthcare Inc.
Filing Date: 2025-04-07
Form: 8-K
Item: Item 1.01
Chunk 1
---
ulgated under the Securities Act of
1933 and (y) the date that the Company obtains stockholder approval (the “ Stockholder Approval”) to (i) approve, for
purposes of complying with Nasdaq Listing Rule 5635(d), the issuance of shares of common stock underlying the Company’s
outstanding Series A Warrants, and (ii) approve a proposed amendment to its amended and restated certificate of incorporation to
increase the total number of shares of common stock authorized for issuance thereunder from 100,000,000 shares to 800,000,000
shares, at its upcoming special meeting of stockholders. Additionally, the Company may not issue more than seven shares of common
stock pursuant to the Sales Agreement prior to the date of the Stockholder Approval as the Company currently has no other authorized
shares of common stock available for issuance. As a result, the Company will likely be unable to utilize the Sales Agreement in the
near term. The Company will pay A. G. P. a commission of 3.0% of the gross sales price of the Shares sold under the Sales Agreement.
The Company has also provided A. G. P. with customary indemnification rights and has agreed to reimburse A. G. P. for certain specified
expenses. The offer and sale of the Shares pursuant to the ATM Offering will terminate upon the earlier of (a) the sale of the
Shares pursuant to the prospectus supplement and the accompanying prospectus filed on April 7, 2025, having an aggregate sales price
of $16,768,099, (b) the expiration of the Registration Statement (as defined below) on the third (3rd) anniversary of the initial
effective date of the Registration Statement pursuant to Rule 415(a)(5) under the Securities Act, or (c) termination of the Sales
Agreement by A. G. P. or the Company pursuant to its terms.

The Shares will be offered and sold pursuant to the Company’s shelf registration statement on Form S-3 (File No. 333-283028). The
Company filed a prospectus supplement, dated April 7, 2025, with the Securities and Exchange Commission relating to the offer by the Company
of up to $16,768,099 of Shares in the ATM Offering.

The description of the Sales Agreement does not
purport to be complete and is qualified in its entirety by reference to the Sales Agreement, a copy of which is filed as Exhibit 10